(Q44168590)

30 November 2017

title

Evaluation of HER-2/neu expression in prostatic adenocarcinoma: a requested for a standardized, organ specific methodology (English)

1 reference

30 November 2017

1 reference

4

Michael O Koch

1 reference

30 November 2017

Katya M Sanchez

1

1 reference

30 November 2017

Christopher J Sweeney

2

1 reference

30 November 2017

Robert Mass

3

1 reference

30 November 2017

George J Eckert

5

1 reference

30 November 2017

William A Geary

6

1 reference

30 November 2017

Lee Ann Baldridge

7

1 reference

30 November 2017

Shaobo Zhang

8

1 reference

30 November 2017

John N Eble

9

1 reference

30 November 2017

Liang Cheng

10

1 reference

30 November 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

30 November 2017

1 reference

30 November 2017

volume

95

1 reference

30 November 2017

issue

8

1 reference

30 November 2017

page(s)

1650-1655

1 reference

30 November 2017

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Growth factors in development, transformation, and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Her-2-neu expression and progression toward androgen independence in human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Immunohistochemical detection of c-erbB-2 protein in human benign and neoplastic prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Her-2/neu oncogene amplification in clinically localised prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Oncogene amplifications in early-stage human prostate carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

Overexpression of her-2/neu in human prostate cancer and benign hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

7 January 2021

Expression of HER2/erbB-2 correlates with survival in osteosarcoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

7 January 2021

Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

7 January 2021

Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

7 January 2021

Immunohistochemical detection of oncogene proteins and neuroendocrine differentiation in different stages of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

7 January 2021

[Immunohistochemical study of c-erbB-2 proto-oncogene product in prostatic cancer]

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

7 January 2021

Expression of NEU/HER-2 oncoprotein (p185neu) in prostate tumors: an immunohistochemical study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

7 January 2021

Prognostic value of c-erbB-2 and epidermal growth factor receptor in stage A1 (Tla) prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

7 January 2021

Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

7 January 2021

Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.10839

7 January 2021

Identifiers

DOI

10.1002/CNCR.10839

1 reference

30 November 2017

1 reference